The joint venture provides pharmaceutical and biotechnology companies the opportunity to manufacture first in human batches faster and closer to the clinical sites. The companies will operate the largest network of Xcelodose® systems worldwide guaranteeing immediate manufacturing capacity.
“This joint venture will create a powerful partnership between two leading providers who share a common commitment to quality, innovation, and building client relationships based on trust and performance” said Derek Hennecke, CEO and president of Xcelience. “Xcelience has more than six years experience in powder in capsule technology and has processed more than 100 clinical supply batches using the Xcelodose technology”, noted Paul Wituschek, global sales and marketing director of Penn. “Penn will be able to immediately leverage this expertise to provide this important accelerated development option to our clients.”